Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
about
Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24Liposomes as vaccine delivery systems: a review of the recent advances.The origin and diversification of the merozoite surface protein 3 (msp3) multi-gene family in Plasmodium vivax and related parasites.Plant expression and characterization of the transmission-blocking vaccine candidate PfGAP50.Antigenicity of a Bacterially Expressed Triple Chimeric Antigen of Plasmodium falciparum AARP, MSP-311 and MSP-119: PfAMSP-Fu35Particle-based platforms for malaria vaccines.Influenza virosomes as vaccine adjuvant and carrier system.The GMZ2 malaria vaccine: from concept to efficacy in humans.Size and sequence polymorphisms in the glutamate-rich protein gene of the human malaria parasite Plasmodium falciparum in Thailand.
P2860
Q33743450-FB0BE36D-6D20-4BF4-976E-201E8B7F6F17Q34418761-9BF0A30B-EE8E-422F-B899-E7892199059DQ35524269-4261EE9B-799A-4637-8AC6-F502728CF270Q35857500-F81E4A47-E4D7-4EF8-AED4-A2DAB489A51AQ36178611-FA1D4A94-3B73-402F-933A-119A01FCD951Q36396040-4B5FF65A-383F-4643-A8E3-3551A8EC9653Q38124062-DF6E77F1-9CF6-414C-BF87-4CAAED52F85DQ38658724-F641DF96-6589-4073-9F7F-61E6F73AEC35Q48022813-E02DCA70-D0BF-48EF-A510-88D60455DDEF
P2860
Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Immunogenicity of a virosomall ...... on to adjuvanted formulations.
@en
Immunogenicity of a virosomall ...... on to adjuvanted formulations.
@nl
type
label
Immunogenicity of a virosomall ...... on to adjuvanted formulations.
@en
Immunogenicity of a virosomall ...... on to adjuvanted formulations.
@nl
prefLabel
Immunogenicity of a virosomall ...... on to adjuvanted formulations.
@en
Immunogenicity of a virosomall ...... on to adjuvanted formulations.
@nl
P2093
P2860
P356
P1433
P1476
Immunogenicity of a virosomall ...... on to adjuvanted formulations.
@en
P2093
Gerd Pluschke
Marco Tamborrini
Mario Amacker
Nicole Westerfeld
Rinaldo Zurbriggen
Sabine A Stoffel
P2860
P2888
P356
10.1186/1475-2875-10-359
P577
2011-12-13T00:00:00Z
P5875
P6179
1029384289